The Six-Minute Walk Test In Children With Sickle Cell Disease

Author(s):  
Jason B. Caboot ◽  
Abbas F. Jawad ◽  
Cheryl Y. Bowdre ◽  
Raanan Arens ◽  
Carole L. Marcus ◽  
...  
2014 ◽  
Vol 18 (1) ◽  
pp. 79-87 ◽  
Author(s):  
Daniela G. Ohara ◽  
Gualberto Ruas ◽  
Isabel A. P. Walsh ◽  
Shamyr S. Castro ◽  
Mauricio Jamami

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 1085-1085
Author(s):  
Geoffrey Bourg ◽  
Laurence Dedeken ◽  
Phu-Quoc Le ◽  
Laurence Rozen ◽  
Safiatou Diallo ◽  
...  

Abstract The six-minute walk test (6MWT) was introduced in adults and children suffering from pulmonary or cardio-vascular conditions to assess their sub-maximal functional exercise capacity. In sickle cell disease (SCD), a reduced 6-minute walk distance was observed in adults with chronic pain, hip avascular necrosis and osteopenia ; and in children with low hemoglobin level, low fetal hemoglobin, a baseline elevated TRV. In a previous study (Dedeken et al., PLoS One 2014), we also showed that abnormal 6MWT was significantly associated with the presence of silent infarct. The aim of our study is to explore the evaluation of the 6MWT over time and to confirm the correlation with the cerebral vasculopathy in a larger cohort. This study was conducted at Hôpital Universitaire des Enfants Reine Fabiola (Brussels, Belgium) and included SCD children older than 6 years, regularly followed between 2011 and 2017 and who had at least two 6MWT. The age-standardized predicted value of the 6-minute walk distance (6MWD) was established as reported by Geiger. The 6MWT was considered as normal if the 6MWD was more than 80% of the age-standardized predicted value. Baseline hematological values, clinical events, cerebro-vascular disease, cardio-pulmonary parameters and disease-modifying treatment (DMT) were compared between those with normal and abnormal 6MWT and according to the 6MWD and between the 1st and the 2nd 6MWT overtime. 118 patients have been assessed twice and had at first evaluation a 6MWD of 90.6% (Range 49-119%), with an abnormal test found in 5.1%. The characteristics of the patients are detailed in the Table 1. The changes of the 6MWD and the biological data over time are detailed in Table 2. After 4 years of follow-up, 77.1% of patients were treated with Hydroxyurea (HU) and 16.6% patients were chronically transfused. In parallel with the increased HU prescribing rate, we have observed a significant increase of the Hb and the MCV and a decrease of reticulocytes and hemolysis parameters. The first 6WMT was performed at the median age of 10.3 years and the last one at the median age of 14.1 years. The median 6MWD increased over time including for non-chronically transfused patients. Girls performed less well in the 6MWT (93% for girls vs. 95.7% for boys; P = 0.03). Acute chest syndrome was significantly more frequent in boys (62%) compare to girls (38.7%). Nevertheless, no other differences were founded between boys and girls regarding biological values, clinical events or DMT. 26.5% of our patients have silent infarcts at a median age of 14.6 years. The 6MWD was the same in patients with and without silent infarcts (92.5% vs. 95% ; P=0.17) even when chronically transfused patients were excluded (94% vs. 95% ; P= 0.20). Patients with silent infarcts have a significant lower hemoglobin level and higher reticulocytes count, neutrophils count, LDH and MCV. In conclusion, the 6MWD observed in our cohort characterized by a very high rate of HU treatment is much higher than published in others series and improved over time. With only 5% of SCD patients having a 6MWD < 80% of the normal predicted value at last evaluation, we were not able anymore to confirm a correlation between the presence of silent infracts and abnormal 6MWT. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 574-574
Author(s):  
Victor R. Gordeuk ◽  
Lori Luchtman-Jones ◽  
Andrew D. Campbell ◽  
Sohail R Rana ◽  
Mehdi Nouraie ◽  
...  

Abstract Abstract 574 Background. Elevated tricuspid regurgitation velocity (TRV) as determined by echocardiography correlates with elevated systolic pulmonary artery pressure and is associated with increased morbidity and mortality in adults with sickle cell disease. The importance of elevated TRV in children and adolescents with sickle cell disease is not known. The Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH) study is an ongoing, longitudinal and observational multicenter study of children with sickle cell disease. Methods. Baseline echocardiography and six-minute walk test were performed prospectively in 361 children and adolescents with sickle cell disease at steady state and then repeat studies were performed in 209 after a median of 22 months of follow up (range 10 months to 36 months), also at steady state. A hemolytic component was derived by principal component analysis of baseline values for reticulocyte count, lactate dehydrogenase, aspartate aminotransferase and total bilirubin. Results. TRV or six-minute walk test were measured at both baseline and follow-up in 193 patients. Twenty-one of these 193 patients had elevated TRV of 2.60 m/sec or higher at baseline. Elevated baseline TRV was associated with high hemolytic rate in 15 patients, defined as hemolytic component above the median for the population studied, and with lower hemolytic rate in six patients. Elevated baseline TRV with high hemolytic rate predicted elevated TRV at follow up (odds ratio 7.7; 95% confidence interval [CI] 2.5 to 24.2; P <0.001) but elevated baseline TRV with lower hemolytic rate did not (odds ratio 1.6; 95% CI 0.2 to 14.1; P = 0.7). Elevated baseline TRV with high hemolytic rate also predicted a decline in the six-minute walk distance by 10% or more at follow-up (hazard ratio 3.9; 95% CI 1.4 to 10.7; P = 0.009). In contrast, higher cardiac output as measured by the left ventricular end diastolic dimension z-score was associated with reduced risk for a decline in the walk distance (hazard ratio 0.7; 95%CI 0.6 to 0.9; P = 0.006). Conclusion. Steady-state TRV elevation in association with a high hemolytic rate occurs on screening in about 8% of children and adolescents with sickle cell disease and is predictive of elevated TRV and reduced six-minute walk distance after approximately two years of follow. Such children may be at risk for adverse clinical consequences of pulmonary hypertension as young adults. Further studies are indicated to identify the molecular mechanisms and to develop appropriate medical management for children and adolescents with this complication. Disclosures: No relevant conflicts of interest to declare.


2014 ◽  
Vol 23 (3) ◽  
pp. 212-217 ◽  
Author(s):  
Rajaa Marouf ◽  
Nasser Behbehani ◽  
Mohammed Zubaid ◽  
Hanan Al Wazzan ◽  
Hadeel El Muzaini ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4788-4788
Author(s):  
Laura M. De Castro ◽  
Jude C Jonassaint ◽  
Charlene Flahiff ◽  
Marilyn J. Telen

Abstract The six-minute walk test (6MWT) is a standardized test use to measure patient cardiopulmonary functional capacity. It is been increasingly used as a measure of overall “functional ability” in chronically ill subjects. The frequent occurrence in sickle cell disease (SCD) of complications such as severe anemia, hypoxemia, and avascular necrosis (AVN) raises questions regarding the capacity of this patient population to perform the 6MWT adequately. This study prospectively evaluated the performance of SCD patients enrolled in a longitudinal prospective study evaluating pulmonary hypertension (pHTN) natural history in a 6MW test. The 6MWT was performed in adult patients with SCD, at steady state. The following 6MWT variables were analyzed: Hemoglobin (Hb) diagnosis, age, Hb level, gender, heart rate (HR) at rest and maximum predicted rate at exercise, distance walked (DW), and percentage (%) of predicted distance walked (%PDW), pulse oxymetry (O2Sat) at rest and at exercise, Wellness scale, Borg scale, reason for resting, and physical limitations in performing the test. In addition, pHTN was evaluated by 2D echo. Patients with a TR jet ≥2.5 m/s were considered to have pHTN. Data from 52 adults (≥ 18 yr, 21 females) were collected and analyzed. Thirty-two (62%) had Hb SS, 13 Hb SC, 6 Hb Sβ+Thal, and 1 Hb SδβThal. TR jet was measurable in 41 patients, and 16 of them (39%) had a TR jet ≥2.5 m/s (range 2.5 – 4.7). Mean age of subjects was 36.5 ± 12.6. Females were older than males. (41.3 ± 2.8 vs. 33.7 ± 2.0; p=0.03). The mean distance walked by all patients was 463.6 meters ± 99.2 (minimum 142, maximum 658). The mean %PDW was 72.07% ± 20.75, range: 24 to 146%. There was no statistical difference in the DW when the different HbS genotypes were compared. As expected, the mean DW was higher in males than females (488 ± 14.4 vs. 427.4 ± 25.1 meters, p&lt;0.5). No gender-related differences were observed in Hb levels (9.4 ± 0.34 and 9.9 ±0.4 for females and males respectively), resting and exercise heart rate, or on the Wellness scale. The mean HR at rest was 75 bpm ± 12; while it was 127 bpm ± 20 at exercise. As anticipated, the HR difference between rest and exercise was statistically significant (p&lt;0.0001, r2= 0.88); when analyzed by gender, this difference remained significant. Mean O2Sat at rest was 98% (SD 1.8, range 93–100%). The mean O2Sat at exercise was 94.9 (SD 3.7, range 82–100%). O2Sat difference between rest and exercise was statistically significant (p&lt;0.0001, 95% CI 2.0 to 3.7, r2= 0.47). No differences were observed when oxygenation was analyzed by gender. Percentage distance walked only correlated with oxygenation at rest (p&lt;0.05; CI 0.00 to 0.52) but not with HR at rest or Hb when data for all patients were evaluated. When only the patients with a measurable TR jet were analyzed, %PDW directly correlated with Hb and inversely correlated with TR jet. Three patients performed the test with supplemental O2. In one patient, the supplemental O2 requirement increased from 2L to 4L during exercise. The Wellness scale scores in the study population ranged from 2 – 5, mean 2.8 ± 0.5. The Borg Dyspnea scale scores ranged from 0.5 to 5, mean 2.20 ± 1.2. The average Borg scale score was found to be lower in males (1.7 ± 1.0) vs. females (2.750 ± 1.4), and that difference was statistically significant (p=0.025). Only one patient required rest during the test due to dyspnea, and 2 patients had physical limitations (one walked with a cane and the other one walked with a limp). No adverse events or arrhythmias were observed during the 6MWT. We conclude that the 6MWT can be efficiently performed by SCD patients. Baseline O2Sat, Hb level and pHTN correlated with a shorter 6-minute walking distance percentage in SCD patients.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2107-2107
Author(s):  
Rudy Chapusette ◽  
Laurence Dedeken ◽  
Phu-Quoc Le ◽  
Catherine Heijmans ◽  
Christine Devalck ◽  
...  

Abstract Abstract 2107 The 6-minute walk test (6MWT) evaluates the sub-maximal functional exercise capacity and can be used together with the tricuspid regurgitant jet velocity (TRV) and pro-BNP to screen pulmonary hypertension in adults with sickle cell disease (SCD). A reduced 6-minute walk distance (6MWD) is observed in adults with SCD with chronic pain, hip avascular necrosis and osteopenia. In children with SCD, baseline elevated TRV is associated with a decline in age-standardized 6MWD. The aim of our study is to explore the submaximal exercise capacity of children with SCD followed at the Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium and to analyze the factors affecting the 6MWT and the 6MWD. Since September 2011, all patients with SCD above 6 years of age were screened with the 6MWT as part of their follow-up in order to test if their functional capacity was altered. The age-standardized predicted value of the 6MWD was established as reported by Geiger. The 6MWT was considered as normal if the 6MWD was more than 80% of the age-standardized predicted value, moderately decreased between 60–80%, and severely altered less than 60%. Baseline hematological values, clinical events, cerebro-vascular disease, cardio-pulmonary parameters and disease-modifying treatment (DMT) were compared between those with normal and abnormal 6MWT and according to the 6MWD. Forty-six patients (20 boys and 26 girls) with a median age of 12 yrs were investigated. Forty-three were HbSS or HbSβ°, 2 HbSC and 1 HbSβ+. Thirty-two patients had a normal 6MWT and 14 an abnormal 6MWT. Only one patient had a severely altered test. These 2 groups were similar for age, sex, genotype and history of vaso-occlusive crisis or acute chest syndrome (ACS) as well as for the number of patients receiving DMT (either hydroxyurea (HU) or chronic transfusion). The proportion of patients with normal, conditional or abnormal transcranial doppler was also similar in both groups. Silent infarct (SI) on routine cerebral magnetic resonance imaging was found in 42.9% in the group with abnormal 6MWT versus only 19.4% in the group with normal 6MWT (p= 0.087). Pulmonary functional test, blood pressure, heart rate, systolic function and TRV were identical in both groups and only one patient had TRV >2.5m/sec. Baseline pulse oxymetry was slightly but significantly decreased in patients with abnormal 6MWT (98 versus 100%; p=0.022). Biological parameters were not statistically different between both groups. The 6MWD was not modified according to Hb, MCV, HbF, LDH and reticulocytes count or previous history of clinical event, except for the presence of SI (Table 1). Patients with or without SI were similar for age, sex, previous ACS or painful crisis as well as for hemolytic parameters (LDH: 945 versus 825 UI/l, p=0.832; reticulocytes: 273 versus 329 × 103/μl, p=0.548) and basal Hb (9.7 versus 8.8 g/dl, p=0.06). However patients without SI had significantly higher HbF and MCV values, and lower PMN count reflecting that most of them were treated with HU. In this cross-sectional study, the majority of children with SCD have a normal 6MWT. Abnormal 6MWT was not predicted by any clinical or biological features despite a trend to more SI in the group of children with abnormal test. In this series with only one high TRV patient, the sole factor which influences the 6MWD is the presence of SI. The lower exercise capacity of children with SCD with silent stroke may reflect some subclinical motor or sensitive impairment. Our data suggest also that HU might prevent SI which needs to be confirmed by larger prospective studies. Table 1. 6-minute walk distance (6MWD) in 46 SCD children according to their biological values and clinical complications Mean 6MWD in meters (SD) p value Mean Age in years (SD) p value Hemoglobin (g/dl) · ≥ 9 (N = 24) 531.5 (95.4) 0.173 11.2 (2.8) <0.001 · < 9 (N = 22) 569.8 (92.2) 14.5 (2.7) MCV (fL) · ≥ 90 (N = 24) 536.1 (100.7) 0.251 12.6 (3.5) 0.518 · < 90 (N = 22) 568.3 (86.8) 13.2 (2.8) HbF (%)* · ≥ 10% (N = 30) 544.0 (101.7) 0.360 13.2 (3.5) 0.352 · <10% (N = 15) 570.1 (81.8) 12.6 (2.4) LDH (UI/l) · ≥ 1000 (N = 14) 526.8 (86.5) 0.229 11.8 (3.0) 0.105 · < 1000 (N = 32) 562.3 (97.4) 13.4 (3.1) Previous ACS* · Yes (N = 38) 548.6 (98.3) 0.625 13.5 (3.1) 0.453 · No (N = 7) 566.9 (85.5) 12.5 (4.2) Silent Infarct · Yes (N = 12) 502.5 (113.9) 0.035 12.1 (2.2) 0.374 · No (N = 34) 568.9 (82.0) 13.2 (3.4) * Missed information for 1 patient. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2482-2482
Author(s):  
Mehdi Nouraie ◽  
Caterina Minniti ◽  
Craig Sable ◽  
Andrew D. Campbell ◽  
Sohail R Rana ◽  
...  

Abstract Background: Sickle cell disease shares common complications such as vasculopathy and organ dysfunction involving the heart, the lungs, the liver and the kidneys with other hemolytic conditions. We hypothesized that a hemolytic vasculopathy may underlie some of these complications. Distinguishing whether a complication is due to hemolysis or to the degree of anemia has been a challenge. Methods: A prospective, multicenter study of 310 children and adolescents with sickle cell disease in steady state was conducted. The associations of measures of hemolysis and of hemoglobin concentration with disease complications were assessed. Principle component analysis was used to develop a hemolytic index from the measurements of reticulocyte count, lactate dehydrogenase, aspartate aminotransfersae and total bilirubin. In order to determine the independent associations of hemolysis with the clinical manifestations of sickle cell disease, we computed correlation coefficient of the hemolytic index with these manifestations that controlled for hemoglobin concentration. P values were adjusted for multiple comparisons. Results: Hemolysis and hemoglobin had no significant correlation with number of the severe pain episodes, acute chest syndrome and priapism. The hemolytic index correlated with history of stroke (r= 0.19, p=0.026), white blood cell count (r=0.22, p&lt;0.001), tricuspid regurgitation velocity (r=0.25, p&lt;0.001), left ventricular mass index (r=0.33, 0&lt;0.001), left ventricular internal diastolic z score (r=0.30, p&lt;0.001) and hemoglobin oxygen desaturation (r=−0.30, p&lt;0.001) but not independently with platelet count and creatinine and six-minute-walk Correlation of clinical outcomes with hemolytic index and hemoglobin concentration in sickle cell cases N Hemolytic index (r and P value) Hemoglobin (r and P value) Hemolytic index adjusted for hemoglobin (partial r and P value) 1 Square roots 2Natural Log 3Adjusted for patient’s height p values are adjusted for 13 comparisons. Number of severe pain episodes in the last year 283 −0.05 (0.4) 0.06 (0.3) −0.02 (0.7) History of acute chest or pneumonia 278 0.11 (0.09) −0.63 (&lt;0.0001) 0.06 (0.3) History of priapism History of stroke 137 0.13 (0.1) −0.63 (&lt;0.0001) 0.06 (0.5) 277 0.14 (0.3) 0.003 (1.0) 0.19 (0.026) Platelet count 1 283 0.32 (&lt;0.0001) −0.35 (&lt;0.0001) 0.11 (0.07) White blood cells 2 283 0.46 (&lt;0.0001) −0.47 (&lt;0.0001) 0.22 (&lt;0.001) Creatinine 1 282 −0.34 (&lt;0.0001) 0.45 (&lt;0.0001) −0.07 (0.2) Systolic blood pressure 283 0.01 (0.8) 0.16 (0.07) 0.14 (0.2) Tricuspid regurgitant jet velocity 264 0.35 (&lt;0.0001) −0.27 (&lt;0.001) 0.25 (&lt;0.001) Left ventricular internal diastolic diameter z score 282 0.53 (&lt;0.0001) −0.50(&lt;0.001) 0.30 (&lt;0.001) Left ventricular mass index1 215 0.51 (&lt;0.0001) −0.44 (&lt;0.001) 0.33 (&lt;0.001) O2 saturation 273 −0.49 (&lt;0.0001) 0.42 (&lt;0.001) −0.30 (&lt;0.001) Six-minute-walk (m)3 228 −0.03 (0.6) 0.17 (0.1) 0.07 (0.3) Conclusion: These observations support the hypothesis that a hemolytic vasculopathy independent of the degree of anemia contributes to the pathogenesis of stroke and pulmonary hypertension and to the development of increased systemic vascular resistance. They also raise the possibility that leukocytosis may in part serve as a predictor of poor outcome by its association with hemolysis. Therapeutic interventions that reduce the rate of hemolysis need to be studied for their potential benefit in decreasing the risk and severity of vasculopathy and the resulting organ damage.


Sign in / Sign up

Export Citation Format

Share Document